• FDA approves Dexycu to treat cataract surgery inflammation

    8 monthes ago - By Healio

    Icon Bioscience reported the FDA approved its new drug application for Dexycu, a dropless therapeutic designed to treat inflammation associated with cataract surgery.
    The current standard treatment after cataract surgery is self-administered medicated eye drops, several times a day over several weeks. The Dexycu treatment is applied as a single injection at the end of surgery, David S. Tierney, MD, president and CEO of Icon Bioscience, said in a press release.
    The treatment uses Icon's Verisome drug delivery technology to dispense a biodegradable
    Read more ...